Equities analysts expect ICU Medical (NASDAQ:ICUI) to post $1.81 earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for ICU Medical’s earnings, with the highest EPS estimate coming in at $1.85 and the lowest estimate coming in at $1.77. ICU Medical reported earnings of $1.68 per share during the same quarter last year, which suggests a positive year over year growth rate of 7.7%. The business is expected to report its next quarterly earnings report on Wednesday, May 9th.
On average, analysts expect that ICU Medical will report full-year earnings of $7.00 per share for the current year, with EPS estimates ranging from $6.90 to $7.16. For the next fiscal year, analysts forecast that the firm will post earnings of $8.84 per share, with EPS estimates ranging from $8.35 to $9.36. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow ICU Medical.
ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, March 1st. The medical instruments supplier reported $2.98 EPS for the quarter, beating analysts’ consensus estimates of $1.04 by $1.94. The business had revenue of $370.12 million during the quarter, compared to analyst estimates of $332.91 million. ICU Medical had a return on equity of 8.42% and a net margin of 5.31%. ICU Medical’s quarterly revenue was up 286.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.20 EPS.
NASDAQ ICUI traded up $5.00 on Friday, reaching $252.40. The company had a trading volume of 91,156 shares, compared to its average volume of 226,203. The firm has a market capitalization of $5,108.32, a P/E ratio of 45.72, a PEG ratio of 2.54 and a beta of 0.42. ICU Medical has a 52-week low of $144.25 and a 52-week high of $265.27.
In other ICU Medical news, Director George A. Lopez sold 7,640 shares of the company’s stock in a transaction on Wednesday, March 21st. The stock was sold at an average price of $253.83, for a total value of $1,939,261.20. Following the completion of the transaction, the director now owns 526,574 shares in the company, valued at approximately $133,660,278.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Scott E. Lamb sold 23,624 shares of the company’s stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $220.00, for a total value of $5,197,280.00. Following the completion of the transaction, the chief financial officer now owns 29,723 shares of the company’s stock, valued at approximately $6,539,060. The disclosure for this sale can be found here. Insiders sold a total of 45,431 shares of company stock valued at $10,662,861 in the last 90 days. Corporate insiders own 13.60% of the company’s stock.
A number of large investors have recently made changes to their positions in ICUI. Exane Derivatives bought a new position in shares of ICU Medical during the 4th quarter worth $100,000. Israel Discount Bank of New York grew its stake in shares of ICU Medical by 74.8% during the 4th quarter. Israel Discount Bank of New York now owns 853 shares of the medical instruments supplier’s stock worth $184,000 after acquiring an additional 365 shares during the period. First Republic Investment Management Inc. bought a new position in shares of ICU Medical during the 4th quarter worth $200,000. Raymond James Trust N.A. bought a new position in shares of ICU Medical during the 4th quarter worth $204,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of ICU Medical by 39.2% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 984 shares of the medical instruments supplier’s stock worth $213,000 after acquiring an additional 277 shares during the period. Hedge funds and other institutional investors own 76.92% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was originally posted by WKRB News and is the sole property of of WKRB News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.wkrb13.com/2018/04/01/zacks-brokerages-expect-icu-medical-icui-to-post-1-81-eps.html.
ICU Medical Company Profile
ICU Medical, Inc develops, manufactures, and sells medical devices used in infusion therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein for use in hospitals and ambulatory clinics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.